Empowered Patient Podcast

Luke Smith, Client Operations Analyst, Central Logic and the Director of the Arizona Surge Line finally has time to reflect on the work that went into managing access to hospitals and post-acute care for patients suffering from COVID-10 throughout the state of Arizona, at one point the number 1 hot spot in the world for positivity.  The Surge Line Access Center worked with public and private organizations to expeditiously transfer patients from a diverse population to the level of care they needed as well as get them back home safely. @CentralLogic #HealthSystems #PatientOutcomes #HealthIT #PublicHealth #Arizona #COVID19 #RevenueCapture #ClinicianEffectiveness #Hospitals #BedVisibility #PatientExperience CentralLogic.com Download the transcript here.

Amy Grover, Director of Patient Advocacy, Catalyst Pharmaceuticals works primarily with patients suffering from Lambert-Eaton Myasthenic Syndrome LEMS an ultra-rare disease which is very similar to a larger rare disease myasthenia gravis MG. Working with the patient community and patient advocacy groups, Catalyst is providing support, tools and resources that for the most part have moved online during the pandemic.  As a seasoned patient advocate, Amy is aware of how unique each patient's journey is and how important their participation is in driving research. @CatalystForRare #RareReason #rarediseases #LEMS #MG #patientadvocate CatalystPharma.com Download the transcript

Sally Embrey, Vice President Public Health and Health Tech, DataRobot is applying knowledge from work as an enterprise AI company to attacking the problem of containing and defeating COVID-19. ContagionNET was created to identify leading and lagging indicators of the next COVID-19 hotspot and to help people understand their status, risk and ability to spread the disease. Combining science, testing data and AI-based technology, models have been created and used by NIH, HHS, FDA and other partners to better allocate resources, recruit for vaccine trials, and make more accurate long-term forecasts. @ContagionNET #DataRobot #COVID19 #pandemic #NIH #PopulationHealth #AI #VaccineTrials #COVIDHotSpots DataRobot.com Download the transcript here

Dr. Stephen Brannan, Chief Medical Officer, Karuna Therapeutics discusses the need for creating and delivering transformative medicines for people living with psychiatric and neurological conditions particularly schizophrenia. Pairing the muscarinic agonist with a pan-cholinergic antagonist that does not cross into the central nervous system, KarXT is mitigating the peripheral side effects like weight gain and sedation but still retaining the benefits from muscarinic agonist. @KarunaPharma $KRTX #NeuroTwitter #CNS #schizophrenia #schizoprenia #Neuroscience KarunaTX.com Download the transcript here

Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others have not been able to reach. Revolo Bio's platform drug candidates '1805 and '1104 are in development for rheumatoid arthritis, uveitis, eosinophilic esophagitis and allergic diseases. @RevoloBio #AutoimmuneDisease #AllergicDisease #RheumatoidArthritis #Uveitis #EosinophilicEsophagitis RevoloBio.com Download the transcript here

Anthony Comfort, VP Product Management, VisiQuate reflects on how far science and technology have come in helping monitor the health of diabetics with a new understanding of chemical changes in the body as well as cognitive and behavioral aspects. With the change from manual monitoring blood glucose readings to continuous data streaming in real time, patients and endocrinologists are able to stitch together data from a variety of sources to come up with personalized plans. Applying AI-enabled models and working with payers, providers and medical device companies, the goal is to optimize outcomes for patients and reduce costs. @VisiQuate #DigitalTransformation #AI #COVID19 #DiabetesManagement #DigitalHealth #precisionmedicine VisiQuate.com Download the transcript here  

Derek Maetzold, President and CEO, Castle Biosciences is harnessing the power of genomics to understand the biology of skin cancer. Castle has developed genomic tests to determine how aggressive melanoma and squamous cell carcinoma are in order to better inform dermatologist and patients about intervention decisions. With both diagnostic and prognostic tests and assist from artificial intelligence machine learning-based algorithms, calculations are made for assessing the risk of developing metastatic disease for each individual patient. @CastleBio #SkinCancer #Melanoma #SquamousCellCarcinoma #GenomicTesting #Dermatology CastleBiosciences.com Download the transcript here

Len May, CEO, EndoCanna Health is aggressively exploring the genes that are associated with metabolism of cannabinoids and aiming for a better understanding of the endocannabinoid system to guide the use of cannabis for a wide range of conditions and disorders. With an eye to the complexity of the cannabis plant, EndoCanna has developed a test to determine an individual's genotype and endocompatibility to identify possible drug interactions, adverse effects and benefits of an optimal ratio of cannabinoids and terpenes endo-aligned dosage. #cannabis #EndocannabinoidSystem #endocompatibility #terpenes #cannabinoids #THC #CBD EndoDNA.com Download the transcript

Evan Levine, Co-Founder and CEO, PsyBio Therapeutics is pursuing a paradigm shift in the treatment of mental illness and other neurological disorders by using psychedelics and hallucinogenics. PsyBio biosynthesizes psilocybin and other psychoactive drugs from different plants  and fungi from genetically-modified bacteria. Under the influence of an anxiogenic molecule in a controlled setting, early clinical trials are showing a change in consciousness and rewiring of the brain to be able to address issues such as depression, anxiety, PTSD and substance abuse. #Psychedelics #Psilocybin #Hallucinogenics #neuropsychiatricdisorders #tryptamines #PTSD #depression PsyBioLife.com Download the transcript here

Michael Tkach, Chief Operating Officer and Chief Behavioral Health Officer, Affinity describes a variety of models for large-scale population healthcare management for Return to Work/Stay at Work in this time of COVID-19. With continuous monitoring, testing and data analysis, risk assessment is being used to keep companies aware of adherence to guidelines and regulations and the physical and mental health of their employees. In addition, Affinity is rolling out pop-up COVID Clinics in business settings and in communities with limited healthcare options to provide testing and COVID related information. @AffinityRTW #MentalHealthMonday #COVID19Testing #workplacetesting #returntowork #WorkplaceMentalHealth #humanresources #mentalhealth AffinityReturntoWork.com/rtw Download the transcript here

Dr. Greg Rippon, Vice President and Chief Medical Partner of Neurology, Genentech shines light on SMA, spinal muscular atrophy, a severe inherited progressive neuromuscular disease and one of the most common rare diseases affecting babies. With the introduction of Evrysdi to the treatment options for SMA, an oral treatment is being tested to increase the production of the functional survival motor neuron protein and thus benefit patients in their motor functioning. @genentech #genentech #SMA #SpinalMuscularAtrophy #Evrysdi #raredisease GENE.com Download the transcript here.

Dr. Sudarshan Hebbar, Chief Medical Officer, CalciMedica talks about developing drugs that are focused on targeting CRAC channels, calcium release activated calcium channels, in order to modulate these channels to help treat diseases that have a significant inflammatory component.  Initially developed drugs for acute pancreatitis targeting both the pancreas and the lung. Now conducting large trial in patients with severe and critical COVID-19 as many of the mechanisms that are shared in the development of lung disease with COVID-19 are shared with acute pancreatitis. Strong evidence that their drug Auxora  might be effective for a variety of disorders that cause lung injury. @CalciMedicaInc #COVID19 #CriticalCare #inflammatorydiseases #pancreatitis #CRACChannelinhibitors CalciMedica.com Download the transcript here

Dr. Aaron Koenig, Senior Medical Director and Mike Quirk, Vice President of pharmacology Sage Therapeutics focus on disorders of cognition and diseases that reflect determinants of impaired cognition such as Alzheimer's, Parkinson's and Huntington's. Their drug Sage-718, a novel mechanism of action, targets a protein in the brain, the NMDA receptor, thought to be the brain's coincidence detector designed to link together information that flows from different neural pathways and perhaps correct some of the symptoms causing functional impairment. @SageBiotech #Alzheimers #Parkinsons #Huntingtons #executivefunction #cognition #neurodegeneration SageRx.com Download the transcript here  

Dr. Travis Mickle President and CEO KemPharm describes the development of AZSTARYS, the stimulant-based methylphenidate prodrug treatment for ADHD one of the most common central nervous system diseases. This prodrug stimulates the norepinephrine dopamine reuptake inhibitor improving concentration, executive function, and irritability and provides for long-acting effect and protection from abuse as it is broken down in the lower GI. Travis' personal experience with ADHD and raising children with ADHD gives him a deep understanding of the challenges facing patients as well as their physicians. @kempharm #Kempharm $KMPH #ADHD #CNS KemPharm.com Download the transcript here.

Dr. Mark Allen, Co-Founder and CEO, Elevian is looking to disrupt the longevity business by developing a recombinant GDF11 to treat and prevent multiple age-related diseases. The first application being investigated is for stroke recovery drawing on the discovery that GDF11 decreases with age and when replenished, returns the brain to a healthier pattern of vascularization. Not looking to extend just the life span, the goal is to target the aging process and extend the healthy lifespan. @ElevianInc #aging #StrokeRecovery #AgeRelatedDisease #GDF11 Elevian.com Download the transcript here.

Dr. Steve Kanes, Chief Medical Officer, Sage Therapeutics takes the view that mental disorders and brain health disorders need to be treated like any other medicine. Driving this paradigm shift is the development of breakthrough zuranalone, an oral limited-time treatment to replace taking medicine chronically for those suffering from major depressive disorder. Clinical trials are showing when people do experience recurrences of MDD and episodes are treated when they occur, there are long and prolonged benefits. @SageBiotech #postpartum #depression #MajorDepressiveDisorder #MDD SageRx.com Download the transcript here.

Louis Martinez, Chief Information Officer, EHR Data shines a light on the decentralization of healthcare data collected by providers, insurance carriers, pharmacists and other medical service providers. With a goal of centralizing disparate health data and providing access at point of care, EHR is using blockchain to collect data globally to allow easy access for patients with an ability to grant permission for access to doctors and other health professionals. The pandemic is driving the need to reduce healthcare costs by eliminating redundant efforts and treatments not in the patient's best interest or long-term wellness and for patients to share data to address population health emergencies. #EHRData #myEHRstory  #Wavemaker #COVID19 #blockchain EHRData.com Download the transcript here  

Vu Truong, CEO, Aridis Pharmaceuticals is taking on the challenge of making an inhaled monoclonal antibody to treat COVID-19 to allow for the easier patient access.  Drawing on their work in infectious diseases and with a number of monoclonal antibodies candidates to treat bacteria infection associated with superbugs and antibiotic resistance, Aridis is  finding ways to overcome lack of usage of similar potent antibodies from Regeneron and Eli Lilly to combat the coronavirus. @Aridis_Pharma #AridisPharma #Aridis #Superbugs #AMR #InfectiousDisease #COVID19 #mAb #MonoclonalAntibody #immunotherapy #RespiratoryInfections #CoronavirusVariants AridisPharma.com Download the transcript here

Niloy Sanyal, Chief Marketing Officer, LeanTaaS is focused on the current state of the healthcare system in this wartime environment. In light of COVID-19 challenges particularly for those patients needing acute care, the need to optimize use of operating rooms, ICU beds, infusion chairs, and medical professionals requires more attention to improving capacity utilization.  Planning for a post pandemic peacetime era using AI tools will give patients quicker access to scarce capacity and drive up medical staff satisfaction. @LeanTaaS #LeanTaaS #COVID19 #DigitalHealth #HealthTech LeanTaaS.com Download the transcript here  

Mariya Pylypiv, Founder and Co-Chairwoman, UpHealth talks about empowering patients suffering from chronic conditions with a global comprehensive digital health technology and tech-enabled services platform. Working with care providers, health systems and payers, UpHealth is addressing the complex medical, behavioral, and social challenges of this fast-growing population with many unmet needs. The mission of UpHealth and their related companies is to provide high quality, affordable and accessible care to people around the world. @UpHealth #Thrasys #Glocal #SPAC #DigitalHealth #COVID19 #HumanizeHealthcare #BeTheChange #healthequity #digitaltransformation UpHealthinc.com Download the transcript here